It truly bothers me that the majority of the arguments and analysis that have appeared both in print and on-line surrounding the Provenge issue have come not from the prostate cancer community, but instead from the financial community! Sure, I understand that there are millions of dollars at stake, but I also understand that there [...]
The controversy that has been haunting the FDA approval of Provenge (sipuleucel-T) still continues with major fireworks on all sides. I have written a number of pieces about Provenge in this blog, so if you are not familiar with this potential new treatment you might want to go back and read them. Pay particular attention [...]
There was just a symposium held at Methodist Hospital in Houston. The day long symposium covered both prostate cancer and kidney cancer. Barbara Christensen attended the kidney cancer side of the lectures and has been publishing on a kidney cancer listserv a summary of the information of what she learned. I think that her first [...]
The April 27th edition of Forbes Magazine (Health Day News) describes a new imaging technique that is currently being studied at the University of Michigan. The original study was published in the April 15 issue of Cancer Research. This technology measures the diffusion of water through tumors. As tumor cells die, the diffusion of water [...]
Brandon Keim wrote a recent blog about the GINA, the Genetic Information Non-Discrimination Act which was passed by the US House on the 25th of April. His actual article can be seen at: http://www.wired.com/medtech/genetics/news/2007/04/gene_act This bill is not new to Congress! The Supporters of GINA have been laboring and lobbying for its approval for well [...]